{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:49:40Z","timestamp":1761742180692,"version":"3.41.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.1023\/a:1021267128567","type":"journal-article","created":{"date-parts":[[2003,3,21]],"date-time":"2003-03-21T00:56:49Z","timestamp":1048208209000},"page":"297-309","source":"Crossref","is-referenced-by-count":35,"title":["Chemoprevention of Prostate Cancer: Current Status and Future Directions"],"prefix":"10.1007","volume":"21","author":[{"given":"Ronald","family":"Lieberman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5098326_CR1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","volume":"51","author":"RT Greenlee","year":"2001","unstructured":"Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 51: 15\u201336, 2001","journal-title":"CA Cancer J Clin"},{"key":"5098326_CR2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0022-5347(17)35487-3","volume":"150","author":"WA Sakr","year":"1993","unstructured":"Sakr WA, Haas GP, Cassin BJ, Pontes JE, Crissman JD: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150: 379\u2013385, 1993","journal-title":"J Urol"},{"key":"5098326_CR3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/978-1-59259-009-4_29","volume-title":"Prostate Cancer in the 21st Century","author":"P Greenwald","year":"2001","unstructured":"Greenwald P, Lieberman R: Chemoprevention trials for prostate cancer. In: Chung L, Isaacs W, Simons J (eds) Prostate Cancer in the 21st Century, Humana Press Inc, Totowa, NJ, 2001, pp 499\u2013518"},{"key":"5098326_CR4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.pcan.4500274","volume":"2","author":"GJ Kelloff","year":"1999","unstructured":"Kelloff GJ, Lieberman R, Brawer MK, Crawford ED, Miller G: Strategies for chemoprevention of prostate cancer. Prostate Cancer Prostate Dis 2: 27\u201333, 1999","journal-title":"Prostate Cancer Prostate Dis"},{"key":"5098326_CR5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0090-4295(01)01416-9","volume":"58","author":"R Lieberman","year":"2001","unstructured":"Lieberman R, Bermejo C, Akaza H, Greenwald P, Fair W, Thompson I: Progress in prostate cancer chemoprevention: Modulators of promotion and progression. Urol 58: 835\u2013842, 2001","journal-title":"Urol"},{"key":"5098326_CR6","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I","volume":"59","author":"DG Bostwick","year":"1987","unstructured":"Bostwick DG, Brawer MK: Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 59: 788\u2013794, 1987","journal-title":"Cancer"},{"key":"5098326_CR7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000019883","volume":"35","author":"J Qian","year":"1999","unstructured":"Qian J, Jenkins RB, Bostwick DG: Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluoresence in situ hybridization. Eur Urol 35: 479\u2013483, 1999","journal-title":"Eur Urol"},{"key":"5098326_CR8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000474164","volume":"30","author":"DG Bostwick","year":"1996","unstructured":"Bostwick DG: Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Eur Urol 30: 145\u2013152, 1996","journal-title":"Eur Urol"},{"key":"5098326_CR9","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/S0002-9440(10)65517-4","volume":"155","author":"AM De Marzo","year":"1999","unstructured":"De Marzo AM, Marchi VL, Epstein JL, Nelson WG: Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Path 155: 1985\u20131992, 1999","journal-title":"Am J Path"},{"issue":"4A","key":"5098326_CR10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0090-4295(00)00939-0","volume":"57","author":"WG Nelson","year":"2001","unstructured":"Nelson WG, De Marzo AM, DeWeese TL: The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. Urol 57(4A): 39\u201346, 2001","journal-title":"Urol"},{"key":"5098326_CR11","first-page":"397","volume":"20","author":"PH Bartels","year":"1998","unstructured":"Bartels PH, Montironi R, Hamilton PW, Vaught DL, Bartelds HG: Nuclear chromatin texture in prostatic lesions. II. PIN and malignancy associated changes. Anal Quant Cytol Histol 20: 397\u2013406, 1998","journal-title":"Anal Quant Cytol Histol"},{"issue":"4A","key":"5098326_CR12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0090-4295(00)00968-7","volume":"57","author":"IJ Powell","year":"2001","unstructured":"Powell IJ, Meyskens FL: African american men and hereditary\/familial prostate cancer: Intermediate-risk populations for chemoprevention trials. Urol 57(4A): 178\u2013181, 2001","journal-title":"Urol"},{"issue":"4A","key":"5098326_CR13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0090-4295(00)00981-X","volume":"57","author":"R Lieberman","year":"2001","unstructured":"Lieberman R: Prostate cancer chemoprevention: Strategies for designing efficient clinical trials. Urol 57(4A): 224\u2013229, 2001","journal-title":"Urol"},{"issue":"6A","key":"5098326_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0090-4295(99)00447-1","volume":"54","author":"ED Crawford","year":"1999","unstructured":"Crawford ED, Rosenbasum M, Ziada AM, Lange PH: Overview: Hormone refractory prostate cancer. Urol 54(6A): 1\u20137, 1999","journal-title":"Urol"},{"key":"5098326_CR15","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1073\/pnas.92.8.3439","volume":"92","author":"NM Greenberg","year":"1995","unstructured":"Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tiley WD, Aspwall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen M: Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92: 3439\u20133443, 1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4A","key":"5098326_CR16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0090-4295(00)00931-6","volume":"57","author":"R Lieberman","year":"2001","unstructured":"Lieberman R, Nelson WG, Sakr WA, Meyskens FL, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM: Executive summary of the national cancer institute workshop: Highlights and recommendations. Urol 57(4A): 4\u201328, 2001","journal-title":"Urol"},{"key":"5098326_CR17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-1-59259-009-4_14","volume-title":"Prostate Cancer in the 21st Century","author":"GR Moria","year":"2001","unstructured":"Moria GR, Tindall DJ: Ligand dependent and independent activation of the androgen receptor. In: Chung L, Isaacs W, Simons J (eds) Prostate Cancer in the 21st Century, Humana Press Inc, Totowa, NJ, 2001, pp 219\u2013239"},{"key":"5098326_CR18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","volume":"411","author":"P Blume-Jensen","year":"2001","unstructured":"Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature 411: 355\u2013365, 2001","journal-title":"Nature"},{"issue":"4A","key":"5098326_CR19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0090-4295(00)00944-4","volume":"57","author":"MS Steiner","year":"2001","unstructured":"Steiner MS, Raghow S, Neubauer BL: Selective estrogen receptor modulators for the chemoprevention of prostate cancer. Urol 57(4A): 68\u201373, 2001","journal-title":"Urol"},{"key":"5098326_CR20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0065-230X(08)60946-X","volume":"43","author":"J Folkman","year":"1985","unstructured":"Folkman J: Tumor angiogenesis. Adv Cancer Res 43: 175\u2013203, 1985","journal-title":"Adv Cancer Res"},{"issue":"4A","key":"5098326_CR21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0090-4295(00)00947-X","volume":"57","author":"J Walczak","year":"2001","unstructured":"Walczak J, Wood H, Wilding G, Williams T, Bishop CW, Carducci M: Prostate cancer prevention strategies using antiproliferative or differentiating agents. Urol 57(4A): 81\u201386, 2001","journal-title":"Urol"},{"issue":"4A","key":"5098326_CR22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0090-4295(00)00945-6","volume":"57","author":"C Myers","year":"2001","unstructured":"Myers C, Koki A, Pamukcu R, Wechter W, Padley RJ: Proapoptotic anti-inflammatory drugs. Urol 57(4A): 73\u201377, 2001","journal-title":"Urol"},{"issue":"4A","key":"5098326_CR23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0090-4295(00)00946-8","volume":"57","author":"RC Bergan","year":"2001","unstructured":"Bergan RC, Waggle DH, Carter SK, Horak I, Slichenmyer W, Myers M: Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer. Urol 57(4A): 77\u201381, 2001","journal-title":"Urol"},{"issue":"4A","key":"5098326_CR24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0090-4295(00)00948-1","volume":"57","author":"AW Tolcher","year":"2001","unstructured":"Tolcher AW, Kennedy A, Padley RJ, Majeed N, Pollak M, Kantoff PW: Other novel agents: Rationale and current status as chemopreventive agents. Urol 57(4A): 86-90, 2001","journal-title":"Urol"},{"issue":"4A","key":"5098326_CR25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0090-4295(00)00943-2","volume":"57","author":"DL Trump","year":"2001","unstructured":"Trump DL, Waldstreicher JA, Kolvenbag G, Wissel PS, Neubauer BL: Androgen antagonists: Potential role in prostate cancer prevention. Urol 57(4A): 64\u201368, 2001","journal-title":"Urol"},{"key":"5098326_CR26","doi-asserted-by":"crossref","unstructured":"Pantuck AJ, Zisman A, Henderson D, Wilson D, Schreiber A, Belldegrun A: New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions. Urol 57(4A): 95\u2013100","DOI":"10.1016\/S0090-4295(00)00950-X"},{"issue":"4A","key":"5098326_CR27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0090-4295(00)00942-0","volume":"57","author":"WG Nelson","year":"2001","unstructured":"Nelson WG, Wilding G: Prevention agent development: Criteria and pipeline for candidate chemoprevention agents. Urol 57(4A): 56\u201364, 2001","journal-title":"Urol"},{"key":"5098326_CR28","first-page":"6777","volume":"61","author":"R Mentor-Marcel","year":"2001","unstructured":"Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A: Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgeneic mice (TRAMP). Cancer Res 61: 6777\u20136782, 2001","journal-title":"Cancer Res"},{"key":"5098326_CR29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/978-1-59259-009-4_28","volume-title":"Prostate Cancer in the 21st Century","author":"F Ferrer","year":"2001","unstructured":"Ferrer F, Simons JW, Rodriguez R: Human gene therapy for urological oncology. In: Chung L, Isaacs W, Simons J (eds) Prostate Cancer in the 21st Century, Humana Press Inc, Totowa, NJ, 2001, pp 483\u2013497"},{"issue":"4A","key":"5098326_CR30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0090-4295(00)00971-7","volume":"57","author":"S Alberts","year":"2001","unstructured":"Alberts S, Blute M: Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia. Urol 57(4A): 188\u2013190, 2001","journal-title":"Urol"},{"issue":"4A","key":"5098326_CR31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0090-4295(00)00970-5","volume":"57","author":"LC Clark","year":"2001","unstructured":"Clark LC, Marshall JR: Randomized controlled chemoprevention trials in populations at very high risk for prostate cancer: Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia. Urol 57(4A): 185\u2013187, 2001","journal-title":"Urol"},{"key":"5098326_CR32","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","volume":"341","author":"EM Messing","year":"1999","unstructured":"Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341: 1781\u20131788, 1999","journal-title":"N Engl J Med"},{"key":"5098326_CR33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0090-4295(94)80015-4","volume":"44","author":"J Ferguson","year":"1994","unstructured":"Ferguson J, Zincke H, Ellison E, Bergstrahl E, Bostwick D: Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urol 44: 91\u201395, 1994","journal-title":"Urol"},{"key":"5098326_CR34","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1159\/000019889","volume":"35","author":"T. H. van der Kwast","year":"1999","unstructured":"van der Kwast Th H, Labrie F, Tetu B: Prostatic intraepithelial neoplasia and endocrine manipulation. Eur Urol 35: 508\u2013510, 1999","journal-title":"Eur Urol"},{"key":"5098326_CR35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0197-2456(94)00XXX-M","volume":"16","author":"P Feigl","year":"1995","unstructured":"Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA Jr, Brawley OW, Ford LG: Design of the prostate cancer prevention trial (PCPT). Control Clin Trials 16: 150\u2013163, 1995","journal-title":"Control Clin Trials"},{"key":"5098326_CR36","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer. Report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90: 1371\u20131388, 1998","journal-title":"J Natl Cancer Inst"},{"key":"5098326_CR37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/bjc.1998.508","volume":"78","author":"RJ Cote","year":"1998","unstructured":"Cote RJ, Skinner EC, Salem CE, Mertes SJ, Stanczyk FZ, Henderson BE, Pike MC, Ross RK: The effect of finasteride on the prostate gland in men with elevated serum prostate specific antigen (PSA) levels. Brit J Cancer 78: 413\u2013418, 1998","journal-title":"Brit J Cancer"},{"key":"5098326_CR38","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1046\/j.1464-410x.1998.00630.x","volume":"81","author":"LC Clark","year":"1998","unstructured":"Clark LC, Dalkin B, Krongrad A, Combs GF, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Roudder J: Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. Br J Urol 81: 730\u2013734, 1998","journal-title":"Br J Urol"},{"key":"5098326_CR39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/jnci\/90.6.440","volume":"90","author":"OP Heinonen","year":"1998","unstructured":"Heinonen OP, Albanes D, Virtamo J, Taylor, PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M, Edwards BK: Prostate cancer and supplementation with alpha tocopherol and beta carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 90: 440\u2013446, 1998","journal-title":"J Natl Cancer Inst"},{"issue":"4A","key":"5098326_CR40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0090-4295(00)00951-1","volume":"57","author":"ED Williams","year":"2001","unstructured":"Williams ED, Brooks JD: New molecular approaches for identifying novel targets, mechanisms and biomarkers for prostate cancer chemoprevention agents. Urol 57(4A): 100\u2013103, 2001","journal-title":"Urol"},{"key":"5098326_CR41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/j.1939-4640.1998.tb01981.x","volume":"19","author":"G Bai","year":"1998","unstructured":"Bai G, Kaspar S, Matusik RJ, Rennie PS, Moshier JA, Krongrad A: Androgen regulation of the human ornithine decarboxylase promoter in prostate cancer cells. J Androl 19: 127\u2013135, 1998","journal-title":"J Androl"},{"key":"5098326_CR42","first-page":"143","volume":"5","author":"RR Mohan","year":"1999","unstructured":"Mohan RR, Challa A, Gupta S, et al.: Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin Cancer Res 5: 143\u2013147, 1999","journal-title":"Clin Cancer Res"},{"key":"5098326_CR43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jnci\/93.1.57","volume":"93","author":"AR Simoneau","year":"2001","unstructured":"Simoneau AR, Gerner EW, Phung M, McLaren CE, Meyskens FL: Alpha-difluoromethylornithine (DFMO) suppresses polyamine levels in the human prostate. Results of a one-month phase II A chemoprevention trial. J Natl Cancer Inst 93: 57\u201359, 2001","journal-title":"J Natl Cancer Inst"},{"key":"5098326_CR44","first-page":"36","volume":"34","author":"U Dunzendorfer","year":"1984","unstructured":"Dunzendorfer U, Releya N, Whitmore WF: Some effects of inhibitors of polyamines synthesis on experimental prostatic cancer. Arzneim Forsch Drug Res 34: 36\u201339, 1984","journal-title":"Arzneim Forsch Drug Res"},{"issue":"4A","key":"5098326_CR45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0090-4295(00)00938-9","volume":"57","author":"D Coffey","year":"2001","unstructured":"Coffey D: Similarities of prostate and breast cancer: Evolution, diet and estrogens. Urol 57(4A): 31\u201339, 2001","journal-title":"Urol"},{"key":"5098326_CR46","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000019912","volume":"35","author":"L Denis","year":"1999","unstructured":"Denis L, Morton MS, Griffiths K: Diet and its preventive role in prostatic disease. Eur Urol 35: 377\u2013387, 1999","journal-title":"Eur Urol"},{"key":"5098326_CR47","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0960-0760(92)90244-D","volume":"43","author":"OP Sharma","year":"1992","unstructured":"Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS: Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol 43: 557\u2013563, 1992","journal-title":"J Steroid Biochem Mol Biol"},{"key":"5098326_CR48","first-page":"4093","volume":"60","author":"S Raghow","year":"2000","unstructured":"Raghow S, Steakley M, Greenberg N, Steiner MS: Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. Cancer Res 60: 4093\u20134097, 2000","journal-title":"Cancer Res"},{"issue":"6A","key":"5098326_CR49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0090-4295(99)00449-5","volume":"54","author":"JP Richie","year":"1999","unstructured":"Richie JP: Anti-androgens and other hormonal therapies for prostate cancer. Urol 54(6A): 15\u201318, 1999","journal-title":"Urol"},{"key":"5098326_CR50","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0090-4295(97)00457-3","volume":"50","author":"VR Staiman","year":"1997","unstructured":"Staiman VR, Lowe FC: Tamoxifen for flutamide and finasteride induced gynecomastia. Urol 50: 929\u2013933, 1997","journal-title":"Urol"},{"key":"5098326_CR51","first-page":"3150","volume":"58","author":"M Yang","year":"1998","unstructured":"Yang M, Sytkowski AJ: Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res 58: 3150\u20133153, 1998","journal-title":"Cancer Res"},{"key":"5098326_CR52","first-page":"3062","volume":"61","author":"C Jiang","year":"2001","unstructured":"Jiang C, Wang Z, Ganther H, Lu J: Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 61: 3062\u20133070, 2001","journal-title":"Cancer Res"},{"key":"5098326_CR53","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/jnci\/90.16.1219","volume":"90","author":"K Yoshizawa","year":"1998","unstructured":"Yoshizawa K, Willett WC, Morris SJ: Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 90: 1219\u20131224, 1998","journal-title":"J Natl Cancer Inst"},{"key":"5098326_CR54","first-page":"169","volume":"7","author":"JE Nelson","year":"2000","unstructured":"Nelson JE, Harris RE: Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs). Results of a case control study. Oncol Rep 7: 169\u2013176, 2000","journal-title":"Oncol Rep"},{"key":"5098326_CR55","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/jnci\/89.1.40","volume":"89","author":"MO Ripple","year":"1997","unstructured":"Ripple MO, Henry WF, Rago RP, Wilding G: Prooxidant\u2013antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 89: 40\u201348, 1997","journal-title":"J Natl Cancer Inst"},{"issue":"2A","key":"5098326_CR56","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(01)01255-9","volume":"58","author":"A Kirschenbaum","year":"2001","unstructured":"Kirschenbaum A, Liu XH, Yao S, Levine AC: The role of cyclooxygenase-2 in prostate cancer. Urol 58(2A): 127\u2013131, 2001","journal-title":"Urol"},{"key":"5098326_CR57","first-page":"4245","volume":"58","author":"XH Liu","year":"1998","unstructured":"Liu XH, Yao S, Kirschenbaum A, Levine AC: NS398, a selective cyclooxygenase-2 inhibitor induces apoptosis and down-regulates bcl-2 expression in LNCAP cells. Cancer Res 58: 4245\u20134249, 1998","journal-title":"Cancer Res"},{"issue":"4A","key":"5098326_CR58","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0090-4295(00)00963-8","volume":"57","author":"LH Grouse","year":"2001","unstructured":"Grouse LH, Munson PJ, Nelson PS: Sequence database and microarrays as tools for identifying prostate cancer biomarkers. Urol 57(4A): 154\u2013160, 2001","journal-title":"Urol"},{"issue":"4A","key":"5098326_CR59","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0090-4295(00)00964-X","volume":"57","author":"CP Paweletz","year":"2001","unstructured":"Paweletz CP, Liotta LA, Petricoin EF III: New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urol 57(4A): 160\u2013164, 2001","journal-title":"Urol"},{"issue":"4A","key":"5098326_CR60","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0090-4295(00)00955-9","volume":"57","author":"J Kurhanewicz","year":"2001","unstructured":"Kurhanewicz J, Swanson MG, Wood PJ, Vigneron DB: Magnetic resonance imaging and spectroscopic imaging: Improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials. Urol 57(4A): 124\u2013129, 2001","journal-title":"Urol"},{"key":"5098326_CR61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/path.892","volume":"195","author":"MA Rubin","year":"2001","unstructured":"Rubin MA: Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate cancer. J Path 195: 80\u201386, 2001","journal-title":"J Path"},{"key":"5098326_CR62","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/pros.10032","volume":"50","author":"KL Meehan","year":"2002","unstructured":"Meehan KL, Holland JW, Dawkins HJS: Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 50: 54\u201363, 2002","journal-title":"Prostate"},{"key":"5098326_CR63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/mc.10019","volume":"33","author":"M Ahram","year":"2002","unstructured":"Ahram M, Best CJM, Flaig MJ, Gillespie JW, Leiva IM, Chuaqui RF, Zhou G, Shu H, Duray PH, Linehan WM, Raffeld M, Ornstein DK, Zhao Y, Petricoin EF III, Emmert-Buck MR: Proteomic analysis of human prostate cancer. Mol Carcinog 33: 9\u201315, 2002","journal-title":"Mol Carcinog"},{"issue":"4A","key":"5098326_CR64","first-page":"205","volume":"57","author":"JL Lee","year":"2001","unstructured":"Lee JL, Lieberman R, Sloan JA, Piantadosi S, Lippman SM: Design considerations for efficient prostate cancer chemoprevention trials. Urol 57(4A): 205\u2013213, 2001","journal-title":"Urol"},{"issue":"4A","key":"5098326_CR65","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0090-4295(00)00978-X","volume":"57","author":"P Keegan","year":"2001","unstructured":"Keegan P, Loughman BF: Early clinical trials of chemopreventive and biologic agents: Designs, populations and endpoints. Urol 57(4A): 216\u2013220, 2001","journal-title":"Urol"},{"issue":"4A","key":"5098326_CR66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0090-4295(00)00977-8","volume":"57","author":"J Beitz","year":"2001","unstructured":"Beitz J: Trial endpoints for drug approval in oncology: Chemoprevention. Urol 57(4A): 213\u2013216, 2001","journal-title":"Urol"},{"key":"5098326_CR67","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0090-4295(01)01436-4","volume":"58","author":"GK Lefkowitz","year":"2001","unstructured":"Lefkowitz GK, Sidhu GS, Torre P, Lepor H, Taneja SS: Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling? Urol 58: 999\u20131003, 2001","journal-title":"Urol"},{"key":"5098326_CR68","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0022-5347(17)35304-1","volume":"151","author":"DW Keetch","year":"1994","unstructured":"Keetch DW, Catalona WJ, Smith DS: Serial prostatic biopsies in men with persistently elevated serum prostatic specific antigen values. J Urol 151: 1571\u20131574, 1994","journal-title":"J Urol"},{"key":"5098326_CR69","first-page":"1055","volume":"69","author":"D Byar","year":"1985","unstructured":"Byar D, Piantadosi S: Factorial designs for randomized clinical trials. Cancer Treat Rep 69: 1055\u20131063, 1985","journal-title":"Cancer Treat Rep"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1021267128567.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1021267128567\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1021267128567.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T18:18:53Z","timestamp":1750961933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1021267128567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":69,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["5098326"],"URL":"https:\/\/doi.org\/10.1023\/a:1021267128567","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"type":"print","value":"0167-7659"},{"type":"electronic","value":"1573-7233"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}